share_log

bluebird bio | 8-K: bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio | 8-K: bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio | 8-K:bluebird bio公佈2024年第三季度業績並重點介紹運營進展和2024年指導
美股SEC公告 ·  2024/11/14 20:08

牛牛AI助理已提取核心訊息

bluebird bio reported Q3 2024 revenue of $10.6M, down from $12.3M YoY, with 57 patient starts completed and 17 more scheduled through 2024. The company has activated over 70 qualified treatment centers, with 40% having initiated or completed treatment for at least one patient. Commercial momentum is evidenced by 30 patient starts already scheduled for 2025.The company's cash position stood at $118.7M as of September 30, including $48M in restricted cash. Management expects current funds to last into Q1 2025 and anticipates reaching quarterly cash flow break-even in H2 2025, contingent on scaling to approximately 40 drug product deliveries per quarter and securing additional financing. Operating expenses showed improvement with R&D expenses decreasing to $23.2M from $58.5M YoY.The company has made significant progress in market access, with over half of U.S. states affirming coverage for LYFGENIA and multiple outcomes-based agreements in place with national commercial payers covering more than 200 million lives. Net loss for Q3 improved to $60.8M compared to $87.2M in the prior year.
bluebird bio reported Q3 2024 revenue of $10.6M, down from $12.3M YoY, with 57 patient starts completed and 17 more scheduled through 2024. The company has activated over 70 qualified treatment centers, with 40% having initiated or completed treatment for at least one patient. Commercial momentum is evidenced by 30 patient starts already scheduled for 2025.The company's cash position stood at $118.7M as of September 30, including $48M in restricted cash. Management expects current funds to last into Q1 2025 and anticipates reaching quarterly cash flow break-even in H2 2025, contingent on scaling to approximately 40 drug product deliveries per quarter and securing additional financing. Operating expenses showed improvement with R&D expenses decreasing to $23.2M from $58.5M YoY.The company has made significant progress in market access, with over half of U.S. states affirming coverage for LYFGENIA and multiple outcomes-based agreements in place with national commercial payers covering more than 200 million lives. Net loss for Q3 improved to $60.8M compared to $87.2M in the prior year.
bluebird bio報告截至2024年第三季度的營業收入爲$1060萬,較去年同期的$1230萬下降,完成了57名患者的治療啓動,並計劃在2024年再安排17名患者。公司已激活超過70個合格的治療中心,其中40%的中心已經爲至少一名患者啓動或完成了治療。商業勢頭得到證明,2025年已經安排了30名患者的治療啓動。截至9月30日,公司現金狀況爲$11870萬,其中包括$4800萬的限制性現金。管理層預計當前的所有基金類型將持續到2025年第一季度,並預計在2025年下半年實現季度現金流收支平衡,這取決於每季度大約交付40個藥品產品和獲得額外融資。營業費用有所改善,研發費用從去年的$5850萬減少至$2320萬。在市場準入方面,公司取得了顯著進展,美國超過一半的州確認了對LYFGENIA的覆蓋,與覆蓋超過20000萬生命的多個國家商業支付方簽訂了以結果爲基礎的協議。第三季度淨虧損改善至$6080萬,相較於去年同期的$8720萬。
bluebird bio報告截至2024年第三季度的營業收入爲$1060萬,較去年同期的$1230萬下降,完成了57名患者的治療啓動,並計劃在2024年再安排17名患者。公司已激活超過70個合格的治療中心,其中40%的中心已經爲至少一名患者啓動或完成了治療。商業勢頭得到證明,2025年已經安排了30名患者的治療啓動。截至9月30日,公司現金狀況爲$11870萬,其中包括$4800萬的限制性現金。管理層預計當前的所有基金類型將持續到2025年第一季度,並預計在2025年下半年實現季度現金流收支平衡,這取決於每季度大約交付40個藥品產品和獲得額外融資。營業費用有所改善,研發費用從去年的$5850萬減少至$2320萬。在市場準入方面,公司取得了顯著進展,美國超過一半的州確認了對LYFGENIA的覆蓋,與覆蓋超過20000萬生命的多個國家商業支付方簽訂了以結果爲基礎的協議。第三季度淨虧損改善至$6080萬,相較於去年同期的$8720萬。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。